Chondroitin Sulfate Market Size, Share, Growth, Trends and Industry Analysis Reportby Susan Hill Business Consultant
The global chondroitin sulfate market size is expected to reach USD 1.4 billion by 2025, accelerating at a CAGR of 3.2% over the forecast period, according to a new report by Grand View Research, Inc. Increasing consumption of joint health supplements owing to rising prevalence of arthritis among obese and geriatric population is projected to drive the product demand.
Clinical efficacy and joint health benefits offered are the major factors triggering the demand for the product. Rising utilization of pharmaceutical grade sodium chondroitin sulfate to cure osteoarthritis is projected to drive industry growth. The market is highly influenced by Chinese dominated product supply, which as per the international nutraceutical industry is inferior and variable in terms of quality, concentration, has missing traceability, and subject to intentional adulteration. Therefore, manufacturers and raw material suppliers have numerous opportunities to supply quality and uniform products through auditable supply chain.
Challenges faced by the industry include adulteration of sodium chondroitin sulfate and the introduction of new joint health ingredients. Fluctuating raw material prices are anticipated to have a negative impact on the product. However, increasing focus on cost-effective process is likely to bolster the volumetric production. The U.S., Germany, the U.K., Japan, and Brazil, among other countries, are the major potential markets for pharmaceutical as well as nutraceutical grade sodium chondroitin sulfate.
The market is fragmented and competitive and marked with the presence of key players across the globe, especially in China. Asian countries, especially Japan and China, are expected to observe remarkable growth over the forecast period. Regional jurisdiction, regulatory scenario, and the availability of raw materials are likely to be regional challenges for the industry.
Further key findings from the report suggest:
- The U.S.
market, in terms of volume, is anticipated to reach 603.5 tons by 2025
sulfate is regulated and approved as a symptomatic slow-acting drug for
osteoarthritis (SYSADOA) in Europe and its intake is preferred along with
Innovations, LLC, a prominent manufacturer of sodium chondroitin sulfate
in the U.S., uses raw materials of European origin and produces
high-quality chondroitin sulfate 90% USP without using any organic solvent
- TSI Group Ltd.;
Qingdao Wan tulmin Biological Products Co. Ltd.; BRF; HeBei SanXin
Industrial Group; Bioiberica S.A.U.; Sigma-Aldrich, Inc.; Sino Siam
Biotechnique Company Limited; Bio-gen Extracts Private Limited; ZPD; and
SEIKAGAKU CORPORATION are some of the key companies present in the
Access full research report on global chondroitin sulfate market:
Created on Nov 6th 2019 08:28. Viewed 121 times.